Study details
Enrolling now
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
NCT IDNCT06414902ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
60
Study length
about 3.1 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing if 18F-AraG PET scans can find tumors in people with esophageal cancer and predict how well they will respond to treatment. The goal is to determine if 18F-AraG PET imaging can detect tumors in participants with esophageal cancer and predict a participant's response to treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ArabinoFuranosylGuanine [18F]F-AraG
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Safety and adverse events (AEs)